Synta's Interim GALAXY Data Encouraging Despite Stock Fall
By Catherine Shaffer
Wednesday, August 8, 2012
Positive interim results from its GALAXY trial of ganetespib and docetaxel for non-small-cell lung cancer (NSCLC) ran Synta Pharmaceuticals Corp.'s stock price off a cliff Thursday.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5476
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.